Launch of Next-Generation Clinical Trial Data Platform
Rutland, MA, Oct. 5, 2017- A brand new clinical trial database and collaborative platform was launched on October 3, with the aim of being the leading source for every clinical trial data need. PrimaryEndpoints.com will serve a broad audience of biotech investors, clinical researchers, patients, and their advocates.
The revolutionary website offers several features previously unavailable, including:
· Crowdsourced trial predictions.
· Data visualizations of clinical trial data.
· Trial events and results.
· Personalized watchlists.
· Access to biotech gurus.
· Trial-centric discussions.
The site’s sleek modern design showcases all of the data available on clinicaltrials.gov, but with more accessibility and ease of use.
The site was founded by Tim Burr, a tech entrepreneur and biotech investor. After much time toiling on clinicaltrials.gov, he knew there was a problem that needed solving. Tim says, ''we wanted to create a platform to ease the tedium and information overload users face when analyzing and sorting through clinical trial data. Given its importance, clinical trial data needs to be ultra-accessible for anyone that needs it.''
What to expect:
People who need to access clinical trial information have been asking for a tool to simplify the monitoring and analyzation of clinical trial data, and Primary Endpoints wants to be the answer. With Primary Endpoints:
· Trial tracking is made easy with customized visual timelines.
· Trial outcomes are predicted by biotech experts.
· Customized notifications of trial updates ensure you are among the first to know.
· Communication with biotech experts and gurus is made easy.
· Join discussion boards and engage with clinical and investing experts.
Be among the first.
Don't miss the opportunity to be among the first to discover this next generation platform for clinical trial data. Visit http://www.primaryendpoints.com/ to experience Primary Endpoints for yourself.
Contact:
Product Manager: Bhavana Singh
Scopic Software 12 Carly Circle Rutland MA 01543 US Phone: (855) 717-5586 (toll free)
Email: marketing@primaryendpoints.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
